3SBio Inc.

1530

KYG8875G1029

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 03:59:52 2024-05-14 am EDT			5-day change	1st Jan Change
6.6 ^HKD	-0.75%		+0.15%	-12.23%

Apr. 22	3Sbio Inc. Announces Management Changes	CI
Apr. 15	3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia	MT

Zhenping Zhu Joins 3SBio Inc. as President of Research & Development and Chief Scientific Officer

January 09, 2017 at 03:00 am EST

3SBio Inc. announced that Zhenping Zhu, MD, PhD, has joined 3SBio as its new President of Research & Development and Chief Scientific Officer. Dr. Zhu has extensive research and development experience within the biotechnology industry. Prior to joining 3SBio, He served as Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation, and President of Kadmon China.

Latest news about 3SBio Inc.

3Sbio Inc. Announces Management Changes	Apr. 22	CI
3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia	Apr. 15	MT
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication	Apr. 12	CI
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.	Mar. 27	CI
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates	Mar. 20	MT
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024	Mar. 20	CI
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product	Jan. 08	MT
Mandi Foam of 3SBio Inc. Approves for Market Launch	Jan. 08	CI
Venus Medtech Names Former 3SBio Finance Chief as CFO	Jan. 04	MT
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China	Nov. 02	MT
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates	23-08-25	MT
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
3SBio Hires Former JPMorgan Exec as CFO	23-07-31	MT
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer	23-07-28	CI
3SBio Rolls Out Pruritus Medication in China	23-07-06	MT
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market	23-07-05	CI
3SBio Inc.'s Equity Buyback announced on July 15, 2022, has expired.	23-06-19	CI
3SBio Enrolls First Patient in Phase 3 Trial of Thrombocytopenia Treatment	23-05-22	MT
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 11 July 2023	23-05-22	CI
3SBio Inc. Announces First Patient Enrolled in the Trial of Phase III Clinical Study of Recombinant Human Thrombopoietin Injection	23-05-22	CI
3Sbio Inc. Announces That the First Patient Recently Been Enrolled in the Trial of Phase Iii Clinical Study of Recombinant Human Thrombopoietin Injection	23-05-22	CI
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on July 11, 2023	23-03-21	CI
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Allorion Therapeutics announced that it has received $50 million in funding from a group of investors	23-03-08	CI

Chart 3SBio Inc.

Duration

Period

More charts

Company Profile

3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Companyâs main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)Î±inhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Companyâs subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for 3SBio Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.156 CNY

Average target price

6.893 CNY

Spread / Average Target

+11.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
3SBIO INC.	-12.23%	2.03B
CSL LIMITED	-2.47%	89.37B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.65B
BIOGEN INC.	-12.92%	32.81B
UCB	+53.93%	25B
BIOMARIN PHARMACEUTICAL INC.	-16.51%	15.29B
INCYTE CORPORATION	-8.27%	12.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.61B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.82%	11.49B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.98B

Biopharmaceuticals

3SBio Inc.

Equities

1530

KYG8875G1029

Pharmaceuticals

Zhenping Zhu Joins 3SBio Inc. as President of Research & Development and Chief Scientific Officer

EPS Revisions